007390 — NatureCell Co Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeMid CapHigh Flyer

Market Cap
KR₩2tn
Enterprise Value
KR₩2tn
Revenue
KR₩32bn

Annual income statement for NatureCell Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	R2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	16,720	22,204	21,252	19,351	32,334
Cost of Revenue
Gross Profit	7,600	9,374	9,099	8,195	16,921
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	31,428	36,468	28,572	30,093	31,759
Operating Profit	-14,708	-14,264	-7,320	-10,742	575
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	-18,870	-32,031	-8,316	-11,571	1,355
Provision for Income Taxes
Net Income After Taxes	-18,870	-32,031	-8,316	-11,438	1,226
Net Income Before Extraordinary Items
Extraordinary Items
Net Income	-18,870	-32,031	-6,814	-11,680	1,226
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	-18,870	-32,031	-6,814	-11,680	1,226
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	-173	-441	-159	-175	19.4
Dividends per Share